Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer
(MedPage Today) -- SAN DIEGO -- A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer in a small pilot study, a researcher reported here.
In the phase I/II trial...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study